Literature DB >> 26383761

[Drug treatment of alopecia].

H Wolff1.   

Abstract

BACKGROUND: Alopecia is the term used to describe hairless areas of the scalp. They can follow a specific pattern, be diffuse or circumscript. Androgenetic alopecia (AGA) follows a pattern: in men thinning of temples and vertex up to total baldness; in women thinning of the midline or parietal area. CAUSES: Lack of iron or cytostatic drugs cause diffuse alopecia, while in autoimmune diseases such as alopecia areata or lichen planus bizarre shapes of hairless areas are observed. TREATMENT: For therapy, the following medications are used: topical minoxidil solution for AGA of men and women; systemic finasteride 1 mg for men with AGA; topical diphencyprone immunotherapy for alopecia areata; systemic antimycotic agents for tinea capitis; antibiotics such as clindamycin and rifampicin for folliculitis decalvans; systemic corticosteroids and isotretinoin for folliculitis et perifolliculitis capitis abscedens et suffodiens; topical corticosteroids for lichen planus and Kossard's frontal fibrosing alopecia.

Entities:  

Keywords:  Alopecia areata; Finasteride; Folliculitis; Lichen planus; Minoxidil

Mesh:

Substances:

Year:  2015        PMID: 26383761     DOI: 10.1007/s00108-015-3763-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  56 in total

1.  [Aseptic femur head necrosis--sequelae of systemic corticosteroid therapy?].

Authors:  C Volkmar; H Wolff
Journal:  Hautarzt       Date:  1998-04       Impact factor: 0.751

2.  Histopathological effects of androgen deprivation in prostatic cancer.

Authors:  F Civantos; M S Soloway; J E Pinto
Journal:  Semin Urol Oncol       Date:  1996-05

3.  Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex.

Authors:  E Ludwig
Journal:  Br J Dermatol       Date:  1977-09       Impact factor: 9.302

4.  Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist.

Authors:  Paradi Mirmirani; Pratima Karnik
Journal:  Arch Dermatol       Date:  2009-12

5.  Treatment of female pattern hair loss with oral antiandrogens.

Authors:  R Sinclair; M Wewerinke; D Jolley
Journal:  Br J Dermatol       Date:  2005-03       Impact factor: 9.302

6.  Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris.

Authors:  S Kossard; M S Lee; B Wilkinson
Journal:  J Am Acad Dermatol       Date:  1997-01       Impact factor: 11.527

Review 7.  Tinea capitis: a current perspective.

Authors:  B E Elewski
Journal:  J Am Acad Dermatol       Date:  2000-01       Impact factor: 11.527

8.  Lichen planopilaris: clinical and pathologic study of forty-five patients.

Authors:  D A Mehregan; H M Van Hale; S A Muller
Journal:  J Am Acad Dermatol       Date:  1992-12       Impact factor: 11.527

Review 9.  Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Authors:  Barnett S Kramer; Karen L Hagerty; Stewart Justman; Mark R Somerfield; Peter C Albertsen; William J Blot; H Ballentine Carter; Joseph P Costantino; Jonathan I Epstein; Paul A Godley; Russell P Harris; Timothy J Wilt; Janet Wittes; Robin Zon; Paul Schellhammer
Journal:  J Urol       Date:  2009-02-26       Impact factor: 7.450

10.  Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci.

Authors:  Regina C Betz; Lynn Petukhova; Stephan Ripke; Hailiang Huang; Androniki Menelaou; Silke Redler; Tim Becker; Stefanie Heilmann; Tarek Yamany; Madeliene Duvic; Maria Hordinsky; David Norris; Vera H Price; Julian Mackay-Wiggan; Annemieke de Jong; Gina M DeStefano; Susanne Moebus; Markus Böhm; Ulrike Blume-Peytavi; Hans Wolff; Gerhard Lutz; Roland Kruse; Li Bian; Christopher I Amos; Annette Lee; Peter K Gregersen; Bettina Blaumeiser; David Altshuler; Raphael Clynes; Paul I W de Bakker; Markus M Nöthen; Mark J Daly; Angela M Christiano
Journal:  Nat Commun       Date:  2015-01-22       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.